CorFlow Therapeutics AG
- Industry
- Medical Devices & Equipment
- Founded Year
- 2016
- Headquarters
- Baar, Switzerland
- Employee Count
- 25
Key People
- Paul Mead - CEO
- Jon H. Hoem - Co-Founder
- Martin T. Rothman - Co-Founder
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's credibility and potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: The CoFI System addresses a significant unmet need in diagnosing and treating microvascular obstruction (MVO) in heart attack patients.
MVO affects over half of acute heart attack patients and is a predictor of heart failure and mortality. The CoFI System's ability to diagnose and treat MVO in real-time during PCI addresses this critical need.
- Competition
-
Aspect: First mover
Summary: CorFlow appears to be the first to offer a real-time diagnostic and therapeutic solution for MVO during PCI.
As a first mover, CorFlow has the advantage of setting industry standards but also faces the challenge of market education and acceptance.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a system that integrates real-time diagnosis and treatment of MVO is moderately complex.
While the technology is innovative, integrating diagnostic and therapeutic functions into a single system presents moderate technical challenges that need to be addressed.
- Patent
-
Aspect: Strong
Summary: CorFlow has developed proprietary technologies for the CoFI System.
The proprietary nature of the CoFI System's technologies provides CorFlow with a competitive edge in the market.
- Financing
-
Aspect: Well-funded
Summary: CorFlow has secured significant funding, including a 44M Series B round.
The substantial funding raised enables CorFlow to advance clinical programs and pursue market clearance for the CoFI System.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The CoFI System is undergoing pivotal trials to gain market clearance.
The ongoing pivotal trials are essential steps toward obtaining regulatory approval and subsequent market entry.
Opportunity Rollup
- Odds of Success
- 3.35
- Peak Market Share
- 3.9
- Segment CAGR
- 4.0%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Interventional Cardiology
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.19 |
| 2 | 0.58 |
| 3 | 1.36 |
| 4 | 2.73 |
| 5 | 3.90 |
Key Takeaway
CorFlow Therapeutics' CoFI System addresses a significant unmet need in interventional cardiology, with strong leadership and substantial funding positioning the company for potential success in the growing cardiovascular device market.